- Home
- PFE vs GILD Comparison
PFE vs GILD Comparison
Compare PFE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFE
- GILD
- Stock Information
- Founded
- PFE 1849
- GILD 1987
- Country
- PFE United States
- GILD United States
- Employees
- PFE N/A
- GILD N/A
- Industry
- PFE Biotechnology: Pharmaceutical Preparations
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFE Health Care
- GILD Health Care
- Exchange
- PFE Nasdaq
- GILD Nasdaq
- Market Cap
- PFE 142.5B
- GILD 144.1B
- IPO Year
- PFE N/A
- GILD 1992
- Fundamental
- Price
- PFE $24.74
- GILD $112.97
- Analyst Decision
- PFE Hold
- GILD Buy
- Analyst Count
- PFE 12
- GILD 23
- Target Price
- PFE $29.36
- GILD $115.68
- AVG Volume (30 Days)
- PFE 43.0M
- GILD 6.3M
- Earning Date
- PFE 10-28-2025
- GILD 08-07-2025
- Dividend Yield
- PFE 6.95%
- GILD 2.80%
- EPS Growth
- PFE N/A
- GILD 496.80
- EPS
- PFE 1.89
- GILD 5.01
- Revenue
- PFE $63,833,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- PFE $0.39
- GILD $2.01
- Revenue Next Year
- PFE N/A
- GILD $4.03
- P/E Ratio
- PFE $13.10
- GILD $22.54
- Revenue Growth
- PFE 13.53
- GILD 3.81
- 52 Week Low
- PFE $20.92
- GILD $77.74
- 52 Week High
- PFE $30.43
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- PFE 47.74
- GILD 44.63
- Support Level
- PFE $24.51
- GILD $113.81
- Resistance Level
- PFE $26.11
- GILD $118.13
- Average True Range (ATR)
- PFE 0.39
- GILD 2.03
- MACD
- PFE -0.05
- GILD -0.79
- Stochastic Oscillator
- PFE 13.72
- GILD 8.52
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).